Key Highlights
- Tempest Therapeutics (Nasdaq: TPST) signed an exclusive option agreement with Senlang for a CD7-targeted lentiviral vector platform and in vivo CAR-T portfolio.
- The deal brings in a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma.
- No Grade 3 or higher CRS or ICANS had been reported as of August 25.
- Shares of Tempest Therapeutics (Nasdaq: TPST) closed up 59% at $1.20.
Option Deal Adds Dual-Targeting Myeloma Asset
Tempest Therapeutics (Nasdaq: TPST) has secured an exclusive option agreement with Senlang to acquire a CD7-targeted lentiviral vector platform alongside an in vivo CAR-T portfolio. The centerpiece of the transaction is a Phase 1 candidate that dual-targets BCMA and GPRC5D for multiple myeloma. Early data show the candidate generating and expanding CAR-T cells in vivo, with no Grade 3 or higher cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome reported as of August 25.
Fits Alongside In-House LNP Platform
The option agreement is designed to complement Tempest Therapeutics' (Nasdaq: TPST) own CD7-targeted lipid nanoparticle in vivo CAR-T platform, which remains in earlier-stage development. By adding a lentiviral vector approach through Senlang, the company gains a second, potentially more durable route to generating CAR-T cells directly inside the body rather than through ex vivo manufacturing. In vivo CAR-T technology has drawn increasing attention across the cell therapy sector as a way to sidestep the cost, time and Manufacturing complexity of traditional ex vivo approaches.
Market Reaction
Shares of Tempest Therapeutics (Nasdaq: TPST) closed up 59% at $1.20 following the announcement, reflecting investor interest in the expanded CAR-T pipeline and the strategic rationale of pairing lentiviral and LNP-based in vivo delivery methods under one roof.
What did Tempest Therapeutics option from Senlang?
An exclusive option on a CD7-targeted lentiviral vector platform and in vivo CAR-T portfolio, including a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma.
What safety data has been reported for the myeloma candidate?
As of August 25, no Grade 3 or higher CRS or ICANS had been reported in early in vivo CAR-T generation and expansion.
How did Tempest Therapeutics (TPST) shares react?
Shares closed up 59% at $1.20 on the day of the announcement.






Please wait processing your request...